Subscribe: PHYSorg.com: Cancer News
http://www.physorg.com/xml-feed/health-news/cancer/
Added By: Feedage Forager Feedage Grade A rated
Language: English
Tags:
american society  breast cancer  breast  cancer  car  cell  cells  patients  researchers  society hematology  study  treatment  university 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: PHYSorg.com: Cancer News

Cancer News - Health News, Medicine News, Cancer



Phys.org provides the latest news on cancer, health, medicines, cancer treatments, cancer research, cancer studies and types of cancer.



 



Transfusion dependence a barrier to quality end-of-life care for some with leukemia

Tue, 12 Dec 2017 03:39:12 EST

For patients with advanced leukemia, access to high-quality end-of-life care appears to be reduced in those dependent on blood transfusions, according to a new study being presented during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. The study associates this reduced access and consequent diminished use of hospice services with a reduced quality of end-of-life care for these patients.



People aged 75 years and older are underrepresented in blood cancer clinical trials

Tue, 12 Dec 2017 03:37:02 EST

In the first comprehensive analysis of clinical trial enrollment among older adults with blood cancers, researchers from the U.S. Food and Drug Administration (FDA) found significant gaps in participation among those aged 75 and older when considered against the incidence of these malignancies in this age group, according to research being presented today during the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta. By comparison, adults under 65 years tend to be overly represented in these trials, despite the fact that a majority of blood cancers are most frequently diagnosed in those over 65 years of age.



Drug suppresses spread of breast cancer caused by stem-like cells

Tue, 12 Dec 2017 03:36:25 EST

Rare stem-like tumor cells play a critical role in the spread of breast cancer, but a vulnerability in the pathway that powers them offers a strategy to target these cells using existing drugs before metastatic disease occurs, report University of California San Diego School of Medicine and Moores Cancer Center researchers.



MRI scans predict patients' ability to fight the spread of cancer

Tue, 12 Dec 2017 03:29:48 EST

A simple, non-invasive procedure that can indicate how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy has been developed by researchers in Liverpool.



Increasing physical activity improves survival in lymphoma patients, researchers say

Mon, 11 Dec 2017 19:50:01 EST

An observational study by researchers at Mayo Clinic has found that increasing physical activity not only decreased the risk of death from all causes but also decreased the risk of death specifically from lymphoma. Lymphoma is a cancer of the lymphatic system, the part of the body's germ-fighting network which includes the lymph nodes (lymph glands), spleen, thymus gland and bone marrow. Lymphoma can affect those areas as well as other organs throughout the body. Study results were presented today at the 59th American Society of Hematology annual meeting in Atlanta by Priyanka Pophali, M.B.B.S., a hematologist at Mayo Clinic.



Insights on how SHARPIN promotes cancer progression

Mon, 11 Dec 2017 16:31:47 EST

Researchers at Sanford Burnham Prebys Medical Discovery (SBP) and the Technion in Israel have found a new role for the SHARPIN protein. In addition to being one of three proteins in the linear ubiquitin chain assembly complex (LUBAC), regulating NFκB and other inflammatory molecules, SHARPIN modulates PRMT5, an epigenetic master switch that controls several proteins linked to melanoma. The research was published in The Journal of Clinical Investigation.



PUMA pathway is a weak link in breast cancer metastasis

Mon, 11 Dec 2017 16:00:01 EST

Substantial advancements have improved the success of chemotherapy, radiation, and surgical treatments for primary breast cancers. However, breast cancer that has spread, or metastasized, to other parts of the body remains a challenge to cure. It is difficult to predict whether a tumor will recur and metastasize, and uncertainty can lead to inadequate or overaggressive treatment.



Glioblastoma survival mechanism reveals new therapeutic target

Mon, 11 Dec 2017 15:52:15 EST

A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation therapy.



ASH: Anti-CD19 CAR T-cell Tx beneficial in B-cell lymphomas

Mon, 11 Dec 2017 13:50:01 EST

(HealthDay)—Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and autologous T cells that express a CD19-directed CAR (CTL019) are effective for refractory B-cell lymphomas, according to two studies published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.



ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

Mon, 11 Dec 2017 13:40:02 EST

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.



Scientists discover possible master switch for programming cancer immunotherapy

Mon, 11 Dec 2017 13:04:54 EST

During infection or tumor growth, a type of specialized white blood cells called CD8+ T cells rapidly multiply within the spleen and lymph nodes and acquire the ability to kill diseased cells. Some of these killer T cells then migrate where required to vanquish the germs or cancers.



Report: New system for more accurate cancer staging to aid precision medicine

Mon, 11 Dec 2017 12:56:36 EST

Adding a blood test called liquid biopsy to a standard tissue biopsy could significantly improve the accuracy of diagnosis and treatment for patients with cancer, according to researchers at Wake Forest Baptist Medical Center.



AML study reports high response rates with combination targeted therapy

Mon, 11 Dec 2017 12:00:04 EST

Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .



Liver cancer: Lipid synthesis promotes tumor formation

Mon, 11 Dec 2017 12:00:03 EST

Lipids comprise an optimal energy source and an important cell component. Researchers from the Biozentrum of the University of Basel and from the University of Geneva have now discovered that the protein mTOR stimulates the production of lipids in liver tumors to satisfy the increased nutrient turnover and energy needs of cancer cells, among other functions. This process has also been observed in patients with liver cancer as the scientists report in Cancer Cell.



A new weapon against bone metastasis? Team develops antibody to fight cancer

Mon, 11 Dec 2017 12:00:01 EST

In the ongoing battle between cancer and modern medicine, some therapeutic agents, while effective, can bring undesirable or even dangerous side effects. "Chemo saves lives and improves survival, but it could work much better if you eliminate unwanted side effects from it," said Princeton University cancer researcher Yibin Kang, the Warner-Lambert/Parke-Davis Professor of Molecular Biology.



Using software, researchers predict tumor markers that could be immune targets

Mon, 11 Dec 2017 11:47:32 EST

University of North Carolina Lineberger Comprehensive Cancer Center scientists have developed a software program that can accurately predict which tumor-specific markers will show up on the surface of leukemia cells in patients who have received stem cell transplants. Researchers plan to use their findings to develop immune-based therapies that target these antigens in leukemia patients.



Pushing the boundaries of melanoma border detection

Mon, 11 Dec 2017 11:36:31 EST

Skin cancer experts will soon be able to benefit from a better way of spotting and identifying lesions, thanks to an improved image segmentation tool developed by computer scientists at Brunel University London.



Use of chemotherapy for early stage breast cancer declines, study says

Mon, 11 Dec 2017 09:32:12 EST

A study of nearly 3,000 women with early stage breast cancer indicates a recent, significant decline in the use of chemotherapy despite the lack of any change in national treatment recommendations or guidelines, according to researchers at the Stanford University School of Medicine and the University of Michigan.



Immunotherapy strategy could be beneficial for relapsed acute myeloid leukemia

Mon, 11 Dec 2017 09:31:40 EST

University of North Carolina Lineberger Comprehensive Cancer Center researchers report that pairing an immunotherapy drug with chemotherapy proved beneficial for some patients with acute myeloid leukemia whose disease did not respond to standard treatment or had relapsed.



Researchers identify epigenetic orchestrator of pancreatic cancer cells

Mon, 11 Dec 2017 09:00:01 EST

Genentech researchers have identified an enzyme that shifts pancreatic cancer cells to a more aggressive, drug-resistant state by epigenetically modifying the cells' chromatin. The study, which will be published December 11 in the Journal of Cell Biology, suggests that targeting this enzyme could make pancreatic cancer cells more vulnerable to existing therapies that currently have only limited effect against this deadly form of cancer.



Drinking and the risk of cancer

Mon, 11 Dec 2017 07:47:04 EST

It's no secret that drinking alcohol is a risk factor for cancer. The National Cancer Institute says alcohol use is associated with a higher risk of developing cancers of the head and neck, esophagus, liver, breast, colon and rectum.



Soy, cruciferous vegetables associated with fewer common breast cancer treatment side effects

Mon, 11 Dec 2017 03:33:22 EST

Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.



Study shows combining chemotherapy with targeted drug boosts response in chronic lymphocytic leukemia

Mon, 11 Dec 2017 03:31:00 EST

Among younger patients newly diagnosed with chronic lymphocytic leukemia (CLL), treatment with a combination of chemotherapy and a molecularly targeted drug significantly improves response over what is typically seen with chemotherapy alone, according to an investigator-initiated multi-center phase II clinical trial.



CAR T, immunotherapy bring new hope for multiple myeloma patients

Mon, 11 Dec 2017 03:26:53 EST

Two investigational immunotherapy approaches, including chimeric antigen receptor (CAR) T cell therapy, have shown encouraging results in the treatment of multiple myeloma patients who had relapsed and were resistant to other therapies. Researchers from the University of Pennsylvania's Abramson Cancer Center administered CAR T cells to patients following chemotherapy, with 64 percent of patients responding in a clinical trial. In a separate study, patients got an infusion of an experimental monoclonal antibody, which resulted in an overall response rate of 60 percent. Both of these investigational approaches targeted a receptor called B-Cell Maturation Antigen (BCMA), which is highly expressed in myeloma and thus a promising target for treatment. These studies will be presented as oral abstracts at the 59th Annual American Society of Hematology Meeting and Exposition in Atlanta.



Low-dose treatment with Il2 across studies shows benefits in chronic graft-versus host

Mon, 11 Dec 2017 03:24:51 EST

Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.



Landmark CAR-T cancer study published

Sun, 10 Dec 2017 11:11:36 EST

Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.



Sequencing offers clues to progression toward multiple myeloma

Sun, 10 Dec 2017 11:11:01 EST

Researchers at Dana-Farber Cancer Institute have carried out the largest genomic analysis of patients with smoldering multiple myeloma (SMM), a precursor to full-blown blood cancer that doesn't show outward symptoms. The next-generation sequencing project "will help to explain the biology of the disease and how it unfolds through time from asymptomatic stages to symptomatic ones," said Mark Bustoros, MD, a postdoctoral fellow in the lab of Irene Ghobrial, MD.



Global CAR T therapy trial shows high rates of durable remission for NHL

Sun, 10 Dec 2017 11:10:44 EST

In a pair of clinical trials stretching from Philadelphia to Tokyo, the chimeric antigen receptor (CAR) T cell therapy Kymriah (formerly known as CTL019) demonstrated long-lasting remissions in non-Hodgkin's lymphoma (NHL) patients. Results from a global, multisite trial will be presented today at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta (Abstract #577). Results from the single-site study, with follow-up extending past two years, will be published today in the New England Journal of Medicine. Both studies were led by Stephen J. Schuster, MD, from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania.



Phase 2 CAR-T study reports significant remission rates at 15-month follow up

Sun, 10 Dec 2017 11:09:56 EST

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta).



Tracking how multiple myeloma evolves by sequencing DNA in the blood

Sun, 10 Dec 2017 08:36:33 EST

Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, eventually, deliver more effective treatments. Researchers now have successfully demonstrated techniques to track these alterations over time by analyzing cell-free DNA (cfDNA) found in blood, according to Jens Lohr, MD, PhD, a hematologist and oncologist at Dana-Farber Cancer Institute.